July 2019
Volume 60, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2019
Interleukin-1β expression is positively correlated with cyclooxygenase-2 expression in basal cell carcinoma of the eyelid
Author Affiliations & Notes
  • Patrick Daigle
    Ophthalmology, Centre hospitalier universitaire de Sherbrooke, Sherbrooke, Quebec, Canada
    The MUHC - McGill Ocular Pathology Laboratory, Montreal, Quebec, Canada
  • Myriam MacDonald
    The MUHC - McGill Ocular Pathology Laboratory, Montreal, Quebec, Canada
  • Ana Beatriz Toledo Dias
    The MUHC - McGill Ocular Pathology Laboratory, Montreal, Quebec, Canada
  • Sabrina Bergeron
    The MUHC - McGill Ocular Pathology Laboratory, Montreal, Quebec, Canada
  • Rami Darwich
    The MUHC - McGill Ocular Pathology Laboratory, Montreal, Quebec, Canada
  • Miguel N Burnier
    The MUHC - McGill Ocular Pathology Laboratory, Montreal, Quebec, Canada
    Ophthalmology, McGill Academic Eye Centre, Montreal, Quebec, Canada
  • Footnotes
    Commercial Relationships   Patrick Daigle, None; Myriam MacDonald, None; Ana Beatriz Dias, None; Sabrina Bergeron, None; Rami Darwich, None; Miguel Burnier, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 3570. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Patrick Daigle, Myriam MacDonald, Ana Beatriz Toledo Dias, Sabrina Bergeron, Rami Darwich, Miguel N Burnier; Interleukin-1β expression is positively correlated with cyclooxygenase-2 expression in basal cell carcinoma of the eyelid. Invest. Ophthalmol. Vis. Sci. 2019;60(9):3570.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Basal cell carcinoma (BCC) is the most common form of skin cancer. Periocular BCCs can be broadly classified as nodular or mophea-type, the latter being associated with a more invasive phenotype. Morphea-type BCCs have been shown to express higher levels of cyclooxygenase-2 (COX-2) than nodular BCCs. Interleukin-1β (IL-1β) has been shown to promote COX-2 expression in several cancers, but its role in BCCs has not been studied extensively. Therefore, the purpose of this study is to compare the expression of IL-1β and COX-2 in nodular and morphea-type BCCs.

Methods : A total of 40 BCCs (nodular: n = 20; morphea-type: n = 20) of the lower lid were evaluated in this study. Immunohistochemical stains were performed for IL-1β (Abcam, clone 11E5, dilution 1:250) and COX-2 (Invitrogen, clone COX 229, dilution 1:50). Two immunohistochemical scores evaluating the intensity (0 = absent, 1= mild or 2= strong) and the distribution (0= absent, 1= focal or 2= diffuse) of the staining were performed.

Results : All 40 cases of nodular and morphea-type BCCs showed some degree of positivity for both IL-1β and COX-2. Morphea-type BCCs were associated with higher immunoreactivity scores than nodular BCCs for both IL-1β (Fisher’s exact test p-value < 0.05) and COX-2 (Fisher’s exact test p-value < 0.05). In addition, a positive correlation between the expression of IL-1β and that of COX-2 was found to be statistically significant (intensity scores: Kendall 2-sided p-value < 0.05; distribution scores: Kendall 2-sided p-value < 0.05).

Conclusions : Our results confirm that morphea-type BCCs express higher levels of IL-1β and COX-2 than nodular BCCs. Moreover, they are the first to demonstrate a significant positive correlation between IL-1β and COX-2 in BCCs. We propose that IL-1β is at least partly responsible for COX-2 expression in BCCs and suggest that its role as a novel therapeutic target in locally invasive and metastatic BCCs should be investigated further.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×